Vascular endothelial growth factor A–heparan sulfate interaction interface (VEGF-HS interface) (VEGF-HS interface)

The Vascular endothelial growth factor A (VEGF-A)–heparan sulfate (HS) interaction interface is a specialized molecular contact area between the heparin-binding domain (HBD) of specific VEGF-A isoforms, such as VEGF165, and heparan sulfate proteoglycans (HSPGs) located on cell surfaces and within the extracellular matrix (ECM). This interaction is a fundamental regulator of angiogenesis, as it sequesters VEGF-A within the ECM to create the chemotactic gradients necessary for directed blood vessel sprouting and protects the growth factor from proteolytic degradation. Furthermore, HS acts as a critical co-receptor that facilitates the assembly and stabilization of the VEGF-VEGFR2 signaling complex, significantly enhancing the potency of VEGF-mediated signaling compared to isoforms that lack the HBD. In pathological conditions like cancer and neovascular age-related macular degeneration (AMD), this interface is exploited to drive uncontrolled vessel proliferation and increased vascular permeability. Therapeutic strategies targeting this interface include the RNA aptamer pegaptanib, which specifically binds the HBD of VEGF165 to prevent its interaction with HS, thereby selectively inhibiting the most potent pro-angiogenic isoforms. Other approaches involve heparan sulfate mimetics, such as muparfostat and pixatimod, which compete for VEGF binding and disrupt the formation of the pro-angiogenic ternary complex. By focusing on this specific interaction, these agents aim to provide a more targeted inhibition of pathological angiogenesis with potentially fewer systemic side effects than pan-VEGF inhibitors.

Other names

Vascular endothelial growth factor A heparin-binding domainVEGF-HSPG interaction siteVEGF165 HBD-HS interfaceVEGF-heparin interaction interfaceVEGF-A–heparan sulfate proteoglycan complex

Competitive inhibition of the VEGF-A heparin-binding domain to prevent its interaction with cell-surface and extracellular matrix-associated heparan sulfate proteoglycans, thereby disrupting the formation of the VEGF-HSPG-VEGFR2 signaling complex and preventing growth factor sequestration.